Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285369345> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W4285369345 abstract "Cardiovascular disease is the leading cause of mortality in the US annually. The underlying cause of mortality in cardiovascular disease is the formation of platelet-rich clots that occlude blood vessels due to aberrant platelet activation. While antiplatelet therapeutic intervention has significantly reduced the risk of an occlusive thrombotic event, many patients remain at risk for a myocardial infarction or stroke. The antiplatelet and antithrombotic effects of omega-6 polyunsaturated fatty acids are primarily attributed to its metabolism to bioactive metabolites by oxygenases such as lipoxygenases (LOX). LOXs are a group of lipid-peroxidizing enzymes named according to the specific position where they add an oxygen to arachidonic acid: 5-LOX, 12-LOX, and 15-LOX. Previous studies from our group have demonstrated that dihomo-γ-linolenic acid and arachidonic acid regulate platelet function through their respective 12-LOX-derived oxylipins, 12(S)-hydroxyeicosatrienoic (12-HETrE) and 12(S)-hydroxyeicosatetraenoic acid (12-HETE). While the expression of 15-LOX in platelets is controversial, platelets have demonstrated the ability to generate the 15-LOX-derived bioactive metabolites. In this study we sought to elucidate the mechanistic effects of 15(S)-hydroxyeicosatrienoic acid (15-HETrE) and 15(S)-hydroxyeicosatetraenoic (15-HETE) on platelet reactivity. Washed human platelets were treated with 15-HETrE or 15-HETE and platelet aggregation, integrin αIIbβ3 activation, calcium mobilization, and granule secretion were quantified. Both 15-HETrE and 15-HETE were shown to inhibit platelet aggregation mediated by collagen. In comparison to vehicle-treated platelets, treatment with 15-HETrE or 15-HETE inhibited agonist-induced intracellular signalling events, including PKC activation, calcium mobilization, and granule secretion. Surprisingly, while 15-HETrE was shown to inhibit platelets through a signalling cascade involving the activation of PPARβ, 15-HETE’s inhibitory effect was shown to involve the activation of PPARα and the inhibition of 12-HETE production. A better understanding of the effects of 15-LOX oxylipins in platelets could lead to the identification of novel antiplatelet therapies." @default.
- W4285369345 created "2022-07-14" @default.
- W4285369345 creator A5011304800 @default.
- W4285369345 creator A5051870360 @default.
- W4285369345 creator A5088307385 @default.
- W4285369345 creator A5088764798 @default.
- W4285369345 creator A5089351110 @default.
- W4285369345 date "2021-09-01" @default.
- W4285369345 modified "2023-10-17" @default.
- W4285369345 title "Abstract P119: The 15-lipoxygenase-derived Oxylipins 15-HETrE And 15-HETE Inhibit Platelet Activation In Part Through Activation Of PPARs" @default.
- W4285369345 doi "https://doi.org/10.1161/atvb.41.suppl_1.p119" @default.
- W4285369345 hasPublicationYear "2021" @default.
- W4285369345 type Work @default.
- W4285369345 citedByCount "1" @default.
- W4285369345 countsByYear W42853693452022 @default.
- W4285369345 crossrefType "journal-article" @default.
- W4285369345 hasAuthorship W4285369345A5011304800 @default.
- W4285369345 hasAuthorship W4285369345A5051870360 @default.
- W4285369345 hasAuthorship W4285369345A5088307385 @default.
- W4285369345 hasAuthorship W4285369345A5088764798 @default.
- W4285369345 hasAuthorship W4285369345A5089351110 @default.
- W4285369345 hasConcept C126322002 @default.
- W4285369345 hasConcept C181199279 @default.
- W4285369345 hasConcept C185592680 @default.
- W4285369345 hasConcept C19038510 @default.
- W4285369345 hasConcept C2777015399 @default.
- W4285369345 hasConcept C2778078955 @default.
- W4285369345 hasConcept C2780857362 @default.
- W4285369345 hasConcept C3018697912 @default.
- W4285369345 hasConcept C543025807 @default.
- W4285369345 hasConcept C55493867 @default.
- W4285369345 hasConcept C71924100 @default.
- W4285369345 hasConcept C89560881 @default.
- W4285369345 hasConcept C98274493 @default.
- W4285369345 hasConceptScore W4285369345C126322002 @default.
- W4285369345 hasConceptScore W4285369345C181199279 @default.
- W4285369345 hasConceptScore W4285369345C185592680 @default.
- W4285369345 hasConceptScore W4285369345C19038510 @default.
- W4285369345 hasConceptScore W4285369345C2777015399 @default.
- W4285369345 hasConceptScore W4285369345C2778078955 @default.
- W4285369345 hasConceptScore W4285369345C2780857362 @default.
- W4285369345 hasConceptScore W4285369345C3018697912 @default.
- W4285369345 hasConceptScore W4285369345C543025807 @default.
- W4285369345 hasConceptScore W4285369345C55493867 @default.
- W4285369345 hasConceptScore W4285369345C71924100 @default.
- W4285369345 hasConceptScore W4285369345C89560881 @default.
- W4285369345 hasConceptScore W4285369345C98274493 @default.
- W4285369345 hasIssue "Suppl_1" @default.
- W4285369345 hasLocation W42853693451 @default.
- W4285369345 hasOpenAccess W4285369345 @default.
- W4285369345 hasPrimaryLocation W42853693451 @default.
- W4285369345 hasRelatedWork W2036856438 @default.
- W4285369345 hasRelatedWork W2059404587 @default.
- W4285369345 hasRelatedWork W2062279965 @default.
- W4285369345 hasRelatedWork W2076598828 @default.
- W4285369345 hasRelatedWork W2081625311 @default.
- W4285369345 hasRelatedWork W2085125044 @default.
- W4285369345 hasRelatedWork W2103618073 @default.
- W4285369345 hasRelatedWork W2147245111 @default.
- W4285369345 hasRelatedWork W2149729250 @default.
- W4285369345 hasRelatedWork W89645382 @default.
- W4285369345 hasVolume "41" @default.
- W4285369345 isParatext "false" @default.
- W4285369345 isRetracted "false" @default.
- W4285369345 workType "article" @default.